Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

MedImmune

Status and phase: Completed; Phase 2

Conditions: Non-Small Cell Lung Carcinoma; Esophagitis; Pneumonitis

Treatments: Drug: Amifostine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00081315

MI-CP079

Details and patient eligibility

About

The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small cell lung cancer (NSCLC) receiving combined modality therapy.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

You may be eligible for this study if you are 18 years of age or older and:

• Have UnResectable Stage IIIA or IIIB Non Small Cell Lung Cancer
• Have never had prior chemotherapy with Paclitaxel or Carboplatin
• Have never had prior thoracic radiation therapy (XRT)

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind